Novel peptide-based immune anticancer agent

By combining bee venom peptide with apoptotic peptide or anticancer agent conjugates, ITGB2 targeting M2 tumor-associated macrophages is solved, and the problem of difficult targeting M2 macrophages in the tumor microenvironment in the prior art is solved. , effective treatment of solid cancer has been achieved, significantly inhibiting tumor growth and metastasis.

CN119072327APending Publication Date: 2024-12-03SHUANGHAI LIFE SCI CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380032964.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-07
Filing Date
2023-04-06
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing anti-cancer treatment methods are low in the treatment of solid cancer, mainly because the inhibitory immune function factors in the tumor microenvironment reduce the activity of immune cells, especially M2 tumor-associated macrophages play a key role in tumor growth and metastasis. , and existing methods are difficult to effectively target these cells.

Method used

The apoptosis of the bee venom peptide or its variant and apoptotic peptide or anticancer agent is used to induce its apoptosis by specifically binding to ITGB2 of M2 tumor-associated macrophages, thereby inhibiting tumor growth and metastasis.

Benefits of technology

It significantly improved the apoptotic effect of M2 tumor-associated macrophages, inhibited tumor growth and metastasis, enhanced anti-cancer activity, and demonstrated the effect of inhibiting tumor cells in three-dimensional cancer organoids.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072327A_ABST
    Figure CN119072327A_ABST
Patent Text Reader

Abstract

The present invention relates to a novel peptide-based immune anticancer agent, to the use of melittin, a variant thereof, or an analog thereof, or a conjugate thereof to a drug, in an immune anticancer agent, the melittin, the variant thereof or the analogue of the melittin, the variant thereof and the analogue of the melittin are specifically combined with ITGB2 expressed by a cell membrane of the M2-type tumor-associated macrophage to kill the M2-type tumor-associated macrophage; conjugates in which melittin, variants thereof, or analogs thereof have been bound to a proapoptotic peptide or an anticancer agent as a drug significantly improve the apoptotic effect of the M2-type tumor-associated macrophages, and thus can be used as an anticancer composition for inhibiting the growth and metastasis of tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to novel peptide-based immune anticancer agents, and to the use of melittin, its variants or analogs thereof, or conjugates thereof linked to drugs as immune anticancer agents. Background Art

[0002] Previous anticancer treatments were studied in the direction of directly attacking cancer cells or strengthening the activity of immune cells in the body that attack cancer cells. However, such anticancer agents also attack other normal cells other than cancer cells, have many side effects such as hair loss, nausea, and vomiting, and also cause additional reactions due to excessive increase of immune cells. Compared with previous chemotherapy or radiation therapy, an anticancer immunotherapy method that can minimize side effects is a method of using the immune system in the body to treat cancer. In such an anticancer immunotherapy method, a cell therapy method that directly injects into the body after activating T cells (including CAR-T), dendritic cells, natural killer cells, etc. as therapeutic immune cells in vitro, and a method for directly activating immune cells present in the body by injecting cancer antigens and immune activating substances into the body, thereby improving the anticancer efficacy of related anticancer vaccines, etc., are being actively carried out. However, such cell therapy agents or cancer vaccines are mainly used in diseases related to blood cancer, and have the disadvantage of very low therapeutic efficacy in most solid cancers. One of the reasons is that there are microenvironmental factors that inhibit immune function around solid cancers. In fact, in the tumor microenvironment, cells that reduce the function of immune cells (myeloid-derived stromal cells (MDSC), regulatory T cells (Treg), tumor-associated macrophages (TAM)) or immunosuppression-inducing cytokines, metabolites, etc.) actively act, thereby sharply reducing the activity of immune-activating substances and therapeutic immune cells. Therefore, the importance of developing therapeutic agents that have anti-cancer effects by regulating only the microenvironment around tumor cells without directly affecting tumor cells and immune cells to block the supply of nutrients to tumor cells and angiogenesis around tumor cells is becoming increasingly important. The tumor microenvironment plays a role in the proliferation and survival of malignant cells, angiogenesis, metastasis, abnormal adaptive immunity, and reduced response to hormones and chemotherapeutic agents, and is therefore considered a major therapeutic target.

[0003] The microenvironment surrounding the tumor is composed of endothelial cells, inflammatory cells, and fibroblasts. In the 1970s, it was found that tumor-associated macrophages (TAMs) play an important role in tumor growth. Tumor-associated macrophages play an important role by being associated with the overall tumor microenvironment such as cancer growth and metastasis. They are divided into two expression types: tumor suppressor M1 macrophages or tumor suppressor M2 macrophages. M1 macrophages have a strong ability to present antigens and are usually activated by interferon-γ, lipopolysaccharide (LPS), and tumor necrosis factor (TNF)-α, playing a pro-inflammatory and bactericidal role. M2 macrophages are known to promote immunosuppression, tumor formation, and angiogenesis by releasing a variety of extracellular matrix components, angiogenesis, and chemokines. Generally, they are induced by IL-4 and IL-13 and distinguished from M1 tumor-associated macrophages by expressing markers such as arginase-1, mannose (MMR, CD206), scavenger receptors (SR-A, CD204), CD163, and IL-10. Tumor-associated macrophages present around tumors are closely related to the growth and metastasis of tumor cells. It is reported that when a large number of M2 tumor-associated macrophages are present around tumors in cancer patients, the prognosis and survival rate of patients are poor. It is reported that M2 macrophages produce cytokines such as IL-10, TGFβ, and CCL18 that promote cancer growth, and receptors such as PDL1 and B7-1 / 2 present on the surface of M2 tumor-associated macrophages inhibit the anti-tumor activity of T cells and NK cells. In the microenvironment where a large number of M2 tumor-associated macrophages exist, tumor growth, differentiation, and metastasis are actively carried out. Therefore, it is necessary to develop targeted therapeutic agents targeting M2 tumor-associated macrophages. Summary of the invention

[0004] Technical issues

[0005] The object of the present invention is to provide a pharmaceutical composition for removing tumor-associated macrophages in the tumor microenvironment.

[0006] Furthermore, an object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer.

[0007] Furthermore, an object of the present invention is to provide a method for treating cancer.

[0008] At the same time, the object of the present invention is to provide the use of the conjugate of the present invention in preparing a pharmaceutical composition for preventing and treating cancer.

[0009] Technical Solution

[0010] In order to achieve the above object, the present invention provides a pharmaceutical composition for removing tumor-associated macrophages in a tumor microenvironment, comprising a conjugate of bee venom peptide, its variants or their analogs combined with a pro-apoptotic peptide or an anticancer agent as an effective ingredient.

[0011] Furthermore, the present invention provides a pharmaceutical composition for preventing or treating cancer, comprising a conjugate of melittin, its variants or their analogs combined with a pro-apoptotic peptide or an anticancer agent as an active ingredient.

[0012] Furthermore, the present invention provides a method for treating cancer, comprising the step of administering a pharmaceutically effective amount of a conjugate of melittin, its variants or their analogs combined with a pro-apoptotic peptide or an anticancer agent to an individual suffering from cancer.

[0013] Meanwhile, the present invention provides the use of a conjugate of beetle venom peptide, its variants or their analogs combined with a pro-apoptotic peptide or an anticancer agent in preparing a pharmaceutical composition for preventing and treating cancer.

[0014] Effects of the Invention

[0015] The melittin, its variants or their analogs of the present invention kill M2 tumor-associated macrophages by specifically binding to ITGB2 expressed on the cell membrane of M2 tumor-associated macrophages. The conjugates in which melittin, its variants or their analogs are combined with pro-apoptotic peptides or anticancer agents as drugs significantly improve the apoptotic effect of the above-mentioned M2 tumor-associated macrophages, so that they can be used as anticancer compositions for inhibiting tumor growth and metastasis. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1a This figure shows the affinity of TAMpep for M2 macrophages confirmed by flow cytometry analysis.

[0017] Figure 1b This is a graph quantifying the affinity of TAMpep for M2 macrophages (*P<0.05 versus the M0 macrophages).

[0018] Figure 2a To identify the relationship between TAMpe and M2 macrophages in M2 / M0 and M1 / M0 ratios by Venn diagram analysis p Diagram of bound proteins.

[0019] Figure 2b The diagram shows proteins that bind to TAMpep in M2 macrophages identified by scatter plot analysis of the M2 / M0 ratio.

[0020] Figure 2cThe diagram shows proteins that bind to TAMpep in M2 macrophages identified by scatter plot analysis of the M1 / M0 ratio.

[0021] Figure 2d The diagram shows proteins that bind to TAMpep in M2 macrophages identified by scatter plot analysis of the M2 / M1 ratio.

[0022] Figure 3 The graph shows LC-MS chromatogram data obtained by reacting cell membrane proteins extracted from M0, M1, and M2 macrophages, respectively, with TAMpep826-biotin.

[0023] Figure 4 A diagram showing the identification of target proteins of TAMpep826 using LC-MS / MS proteomics.

[0024] Figure 5 It is a diagram showing the conditions of quantitative real-time polymerase chain reaction (Quantitative RT-PCR).

[0025] Figure 6 The figure shows the expression of ITGB2 messenger RNA (mRNA) in M2 macrophages.

[0026] Figure 7 The figure shows the confirmation of ITGB2 protein expression in M2 macrophages.

[0027] Figure 8 The figure shows the expression of ITGB2 protein in M2 macrophages confirmed by immunofluorescence analysis.

[0028] Fig. 9 The diagram shows the confirmation of ITGB2 expression in the cell membrane of M2 macrophages.

[0029] Fig.10 The diagram shows the interaction between TAMpep826 and ITGB2 confirmed in M2 macrophages by a pull-down assay.

[0030] Fig.11 The figure shows the confirmation of the interaction between TAMpep826 and ITGB2 in M2 macrophages by immunofluorescence analysis.

[0031] Fig.12 and Fig.13 The figure shows the binding site of TB511 and ITGB2 confirmed by docking simulation.

[0032] Fig.14Schematic diagram showing that the anti-CD18 antibody used in the preparation of the ITGB2-binding ADC of the present invention specifically binds to the active conformation (extended-open form) in the M2 TAM of CD18.

[0033] Fig.15 This is a picture obtained after ITGB2 was fixed on the surface of the sensor chip.

[0034] Fig.16 This is a diagram showing the binding ability of anti-ITGB2 antibodies to ITGB2 protein confirmed by surface plasmon resonance (SPR).

[0035] Fig.17 This is a diagram showing the binding ability between melittin-dKLA and ITGB2 protein confirmed by surface plasmon resonance.

[0036] Fig.18 A diagram showing the confirmation of ITGB2 mRNA expression in a cell model for ITGB2 expression inhibition established by Crispr / cas9 in M2 macrophages.

[0037] Fig.19 This figure confirms the apoptosis-reducing effect of melittin-dKLA in M2 macrophages by inhibiting ITGB2 expression.

[0038] Fig. 20 The graph confirms the apoptosis-inducing reducing effect of TB511 (TAMpep826-dKLA) in M2 macrophages by inhibiting ITGB2.

[0039] Fig.21 This figure confirms the apoptosis-inducing reducing effect of TB511 by the ITGB2 antibody in M2 macrophages.

[0040] Fig. 22 and Fig.23 The figure shows the confirmation of the effect of TB511 in breast cancer three-dimensional (3D) organoids.

[0041] Fig.24 and Fig.25 This figure shows the confirmation of the effect of TB511 in lung cancer three-dimensional organoids.

[0042] Fig.26 A diagram showing the confirmation of the effect of M-DM1 in lung cancer three-dimensional organoids.

[0043] Fig. 27 and Fig.28 The figure shows the confirmation of the effect of TB511 in three-dimensional organoids of lung cancer resistant to anticancer drugs.

[0044] Fig.29 and Fig.30 A diagram showing the effect of TB511 in three-dimensional organoids of prostate cancer resistant to anticancer drugs.

[0045] Fig.31 A diagram showing the confirmation of the effect of CD18-DM1 in breast cancer three-dimensional organoids.

[0046] Fig.32 A diagram confirming the effect of CD18-MMAE in breast cancer three-dimensional organoids.

[0047] Fig.33 and Fig.34 The diagram shows the confirmation of the effects of ADC (CD18-DM1 and CD18-MMAE) in lung cancer three-dimensional organoids.

[0048] Fig.35 and Fig.36 The diagram shows the confirmation of the effects of ADC (CD18-DM1 and CD18-MMAE) in three-dimensional organoids of lung cancer resistant to anticancer drugs.

[0049] Fig.37 and Fig.38 The figure shows the confirmation of the effect of ADC (CD18-DM1 and CD18-MMAE) in three-dimensional organoids of prostate cancer resistant to anticancer drugs. DETAILED DESCRIPTION

[0050] Best Mode for Carrying Out the Invention

[0051] Hereinafter, the present invention will be described in detail with reference to the accompanying drawings and by examples of the present invention. However, the following examples are only used to illustrate the present invention, and the present invention is not limited to these embodiments. When it is judged that the specific description of the technology or structure that is clear to the ordinary technicians in the technical field to which the present invention belongs may confuse the gist of the present invention, its detailed description will be omitted. The present invention can have various modifications and references within the scope of the attached invention claims and the equivalent scope interpreted therefrom.

[0052] Furthermore, the terminology used in this specification is used to appropriately describe the preferred embodiments of the present invention, and may vary depending on the intention of the user, the operator, or the conventions of the technical field to which the present invention belongs. Therefore, these terms should be defined based on the full text of this specification. In the full text of the specification, when it is mentioned that a part "includes" a certain structural element, unless there is a special record to the contrary, it means that other structural elements may also be included, rather than excluding other structural elements.

[0053] Unless otherwise defined, all technical terms used in the present invention are used with the meanings commonly understood by those skilled in the art in the art to which the present invention belongs. In addition, although preferred methods or samples are described in this specification, similar or equivalent methods or samples are also included in the scope of the present invention. The contents of all publications described as references in this specification are integrated into the present invention.

[0054] Throughout this specification, not only single-letter or three-letter expressions of naturally occurring amino acids are used, but also three-letter expressions are used for other amino acids such as Aib (α-aminoisobutyric acid) and Sar (N-methylglycine). In addition, the amino acids expressed by abbreviations in the present invention are recorded according to the IUPAC-IUB nomenclature as follows.

[0055] Alanine: A, Arginine: R, Asparagine: N, Aspartic acid: D, Cysteine: C, Glutamic acid: E, Glutamine: Q, Glycine: G, Histidine: H, Isoleucine: I, Leucine: L, Lysine: K, Methionine: M, Phenylalanine: F, Proline: P, Serine: S, Threonine: T, Tryptophan: W, Tyrosine: Y and Valine: V.

[0056] In one embodiment, the present invention relates to a pharmaceutical composition for removing tumor-associated macrophages (TAM) in a tumor microenvironment, comprising a conjugate of melittin, its variants or their analogs combined with a pro-apoptotic peptide or an anticancer agent as an active ingredient.

[0057] In one example, the tumor-associated macrophages may be M2 tumor-associated macrophages expressing integrin beta 2 (IGBT2).

[0058] In one example, the composition can remove only M2 macrophages without removing M1 macrophages.

[0059] In one example, the melittin may comprise the amino acid sequence of SEQ ID NO: 1.

[0060] In one example, the variant of melittin may be a peptide lacking the amino acids at positions 1 to 7 in the amino acid sequence of sequence 1, and may include the amino acid sequence of sequence 2.

[0061] In one example, ITGB2 may comprise the amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 8.

[0062] In one example, the above-mentioned melittin, its variants or their analogs can specifically bind to the extended active conformation of ITGB2 (CD18).

[0063] In one example, melittin, its variants or their analogs can bind to amino acids 466 to 565 of ITGB2.

[0064] In one example, the composition may include a peptide comprising the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6.

[0065] In one example, the conjugate in which bee venom peptide, its variants or their analogs are combined with a pro-apoptotic peptide or an anticancer agent can be a peptide-drug conjugate (PDC), and the PDC can be bee venom peptide-dKLA comprising the amino acid sequence of sequence 5, can be TB511 comprising the amino acid sequence of sequence 6, or can be M-DM1 in which maleimide-modified bee venom peptide is conjugated with the drug DM1.

[0066] In one example, LEU (6) of TB511 can bind to LEU (528), THR (538), LEU (556), CYS (557) and PHE (558) sites of ITGB2, and TRP (12) of TB511 can bind to GLU (466), ILE (469), CYS (470) and ARG (471) of ITGB2.

[0067] In one example, melittin, its variants or their analogs and the pro-apoptotic peptide or anti-cancer agent can be covalently bound via a linker or non-covalently bound without a linker.

[0068] In one example, the linker may comprise the amino acid sequence of SEQ ID NO: 3.

[0069] In one example, melittin, its variants or analogs thereof may further comprise a targeting sequence, a tag, a labeled residue or an amino acid sequence designed for a specific purpose such as increasing half-life or stability.

[0070] In one embodiment, the pro-apoptotic peptide can be selected from KLA, alpha-defensin-1, BMAP-28, Brevenin-2R, Buforin IIb, cecropin A-Magainin 2 (CA-MA-2), cecropin A, cecropin B, chrysophsin-1, D-K6L9, Gomesin, Lactoferricin B, LLL27, LTX-315, Magainin 2 n2), Magainin II-bombesin conjugate (MG2B), Pardaxin and a combination thereof, the D-isomer KLA is more preferred and may contain the amino acid sequence of sequence 4.

[0071] In one embodiment, the anticancer agent can be selected from 7-ethyl-10-hydroxycamptothecin (SN-38, 7-Ethyl-10-hydroxy-camptothecin), daunorubicin, doxorubicin, epirubicin, idarubicin, pixantrone, sabarubicin, valrubicin, paclitaxel, docetaxel, mechloethamine, phenoxyacetylcholine, chloramphenicol ... Chlorambucil, phenylalanine, mustard, cyclophosphamide, ifosfamide, carmustine (BCNU), lomustine (CCNU), streptozotocin, busulfan, thiotepa, cisplatin, carboplatin, dactinomycin (actinomycin D), plicamycin, mitomycin C, vincristine, vinblastine, teniposide, topotecan, irinotecan, uramustine, melphalan, bendamustine, dacarbazine, temozolomide, altretamine, duocarmycin, nedaplatin, oxaliplatin, satraplatin, triplatin tetranitratetetranitrate), 5-fluorouracil, 6-mercaptopurine, capecitabine, cladribine, clofarabine, cystarbine, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, pemetrexed The invention can be selected from the group consisting of metrexed, pentostatin, thioguanine, etoposide, mitoxantrone, izabepilone, vindesine sulfate, vinorelbine, estramustine, maytansine, DM1 (mertansine), DM4, dolastatin, auristatin E, auristatin F, monomethyl auristatin E (MMAE), monomethyl auristatin F and their derivatives, which can be DM1 or MMAE.

[0072] In one example, the above-mentioned melittin, its variants or their analogs and the pro-apoptotic peptide or anti-cancer agent can be linked via a chemical linker or by direct conjugation. The chemical linker can be linked via the amine, carboxyl or sulfhydryl groups on melittin, its variants or their analogs and the pro-apoptotic peptide or anti-cancer agent.

[0073] In one embodiment, the chemical linker may include a carbodiimide, N-hydroxysuccinimide ester (NHS ester), imidoester, pentafluorophenyl ester, hydroxymethylphosphine, maleimide, haloacetyl, pyridyldisulfide, thiosulfinic acid, Thiosulfonate, vinylsulfone and their The functional groups in the group can be selectedFrom EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide), DCC (N,N'-dicyclohexylcarbodiimide), SATA (succinimidyl acetylthioacetate), sulfo-SMCC (sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate), DMA (dimethyl diimidoadipate·2HCl), DMP (dimethyl diimidopimelate·2HCl), DMS (dimethyl diimidosuberate·2HCl), DTBP (3,3'-dithiobispropionimidate dimethyl ester·2HCl), sulfo-SIAB (sulfosuccinimidyl (4-iodoacetic acid) aminobenzoate), SIAB (succinimidyl (4-iodoacetic acid) aminobenzoate), SBAP (succinimidyl 3-(bromoacetyl) propionate), SIA (succinimidyl iodoacetate), SM(PEG)n (succinimidyl-[N-maleimidopropionamido]-#ethylene glycol ester, wherein n=2, 4, 6, 8, 12 or 24), SMCC (succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate), LCSMCC (succinimidyl-[4-(N-maleimidomethyl) cyclohexane-1-carboxylate), sulfo-EMCS (N-ε ester), EMCS (N-ε sulfo-GMBS (N-γ ester), GMBS (N-γ ester), sulfo-KMUS (N-κ ester), sulfo-MBS (m-maleimidobenzoyl-N-hydroxysulfosuccinimide ester), MBS (m-maleimidobenzoyl-N-hydroxysuccinimide ester), sulfo-SMPB (sulfosuccinimidyl 4-(p-maleimidophenyl) butyrate), SMPB (succinimidyl 4-(maleimidophenyl) butyrate), AMAS (N-α- Maleimidoacetyl-oxysuccinimide ester), BMPS (N-β-maleimidopropoxysuccinimide ester), SMPH (succinimidyl 6-[(β-maleimidopropionamido)hexanoate]), PEG12-SPDP (2-pyridyldithiol-tetraoxooctacyclodecane-N-hydroxysuccinimide), PEG4-SPDP, sulfo-LCSPDP (6-hexanoic acid sulfosuccinimide ester), SPDP (3-(2-pyridyldithio) propionate succinimide ester), LC-SPDP (6-adipate succinimide ester), SMPT (4-succinimidyloxycarbonyl-α-permethyl-(2-pyridyldithio) propionate) toluene), DSS (disuccinimidyl suberate), BS(PEG)5 (bis(succinimidyl)pentyl(ethylene glycol)), BS(PEG)9 (bis(succinimidyl)nonyl(ethylene glycol)), BS3 (bis[sulfosuccinimidyl]suberate), BSOCOES (bissulfone), PDPH (3-(2-pyridyldithio)propionylhydrazide), DSG (disuccinimidyl glutarate), DSP (bis[succinimidyl propionate] dithioate), BM(PEG)n (1,8-dimaleimido-ethylene glycol, n=2 or 3), BMB (1,4-dimaleimidobutane), BMDB (1,4-dimaleimido-2,3-dihydroxybutane), BMH (bismaleimidohexane), BMOE (bismaleimidoethane), DTME (disulfide bismaleimidoethane), TMEA (tris(2-maleimidoethyl)amine), DSS (disuccinimidyl suberate), DST (disuccinimidyl tartrate), DTSSP (3,3'-dithiobis[sulfosuccinimidyl propionate]), EGS (ethylene glycol bis(succinimidyl succinate)), sulfo-EGS (ethylene glycol-bis[succinimidyl succinate] disulfonate) and TSAT (trisuccinimidyl aminotriacetate), DFDNB (1,5-difluoro-2,4-dinitrobenzene) and their combinations.

[0074] In the present invention, preferably, the above-mentioned peptide has the above-mentioned amino acid sequence, but is not limited thereto. According to a preferred embodiment of the present invention, in the above-mentioned peptide, the ratio of the above-mentioned amino acids is 50% or more, preferably 60% or more, more preferably 70% or more, even more preferably 80% or more, further preferably 90% or more, and most preferably up to 100%.

[0075] In the present invention, the peptides may further comprise targeting sequences, tags, labeled residues, additional amino acid sequences proposed for the purpose of increasing the half-life or stability of the peptides. In addition, the peptides of the present invention may be linked to partners such as effectors, drugs, prodrugs, toxins, peptides, and delivery molecules.

[0076] In the present invention, the peptide can be prepared into a pharmaceutically acceptable salt form. Specifically, the salt can be formed by adding an acid, for example, by adding an inorganic acid (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, etc.), an organic carboxylic acid (e.g., acetic acid, trifluoroacetic acid and other halogenated acetic acid, propionic acid, maleic acid, succinic acid, malic acid, citric acid, tartaric acid, salicylic acid), and an acidic sugar (glucuronic acid, galacturonic acid, gluconic acid, ascorbic acid), an acidic polysaccharide (e.g., hyaluronic acid, chondroitin sulfate, arginine), an organic sulfonic acid (e.g., methanesulfonic acid, p-toluenesulfonic acid) containing sulfonic sugar esters such as chondroitin sulfate, etc. to form a salt.

[0077] The term "conjugate" of the present invention refers to a conjugate of bee venom peptide, its variants or their analog peptides combined with a pro-apoptotic peptide or an anticancer agent, which can target M2 tumor-associated macrophages. The conjugate can damage the mitochondria of macrophages by combining with targeted M2 macrophages, thereby inhibiting tumor growth and metastasis, and can inhibit cancer by selectively inhibiting peripheral angiogenesis.

[0078] That is, the anticancer activity of the conjugate of the present invention can be improved compared to the anticancer agent, but the present invention is not limited thereto.

[0079] In the present invention, the above-mentioned conjugate can be connected to melittin, its variants or their analogs and pro-apoptotic peptides through GGGGS linker (sequence 3), or can be connected to anticancer agents such as doxorubicin, methotrexate, Entinostat, Cladribine, Pralatrexate and Lorlatinib through SPDP linker. In addition, it can be directly connected to maytansine DM1, maytansine DM3 and maytansine DM4 without a linker, but it is not limited thereto.

[0080] That is, the conjugate of the present invention may be in a form in which melittin, its variants or analogs thereof are linked to an anticancer agent via a chemical linker or directly linked to the anticancer agent, but is not limited thereto.

[0081] The term "melittin (MEL)" of the present invention is a peptide that constitutes the main component of bee venom. The above-mentioned term "bee venom (BV)" used in the present application is a mixture of acidic and alkaline secretions produced in the abdomen of honey bees (Apis mellifera), in the form of a colorless bitter liquid, and its main components are melittin, apamin, and mast cell degranulating (MCD) peptides as peptides and phospholipase A2 (phospholipase A2; PLA2) as an enzyme, etc., and also contain trace amounts of various components. Therefore, the melittin of the present invention can be isolated from the bee venom of honey bees (Apis mellifera), but is not limited to this.

[0082] The term "peptide" used in the present invention is an amino acid polymer, and may contain not only natural amino acids but also non-proteinaceous amino acids as structural elements.

[0083] The term "variant" as used in the present invention refers to a corresponding amino acid sequence comprising at least one amino acid difference (substitution, insertion or deletion) when compared to a standard substance. In a specific embodiment, a "variant" has high amino acid sequence homology and / or protective amino acid substitutions, deletions and / or insertions when compared to a standard sequence.

[0084] The term "peptide analogs" used in the present invention may include analogs in which the side chains or α-backbones of amino acids are replaced by one or more other functional groups. Examples of peptide analogs with modified side chains or backbones may be hydroxyproline or N-methylglycine "peptoids" in which the pyrrolidine ring is replaced by a hydroxyl group, but are not limited thereto. The types of peptide analogs are well known in the technical field to which the present invention belongs.

[0085] The protein variants of the present invention are also construed to include variants in which amino acid residues are protectively substituted at specific amino acid residue positions.

[0086] In the present invention, "protective substitution" includes the deformation of variants including substitution of one or more amino acids with amino acids having similar biochemical properties that do not cause loss of biological or biochemical functions of the melittin protein variant. "Protective amino acid substitution" is a substitution in which an amino acid residue is replaced with an amino acid residue having a similar side chain. The classification of amino acid residues having similar side chains is defined in the technical field to which the present invention belongs and is well known. These categories include amino acids with basic side chains (e.g., lysine, arginine, histidine), amino acids with acidic side chains (e.g., aspartic acid, glutamic acid), amino acids with uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), amino acids with nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), amino acids with beta-branched side chains (e.g., threonine, valine, isoleucine), and amino acids with aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0087] The peptides of the present invention can be prepared by standard synthesis methods, recombinant expression systems or any other method in the art to which the present invention belongs. Therefore, the peptides of the present invention can be synthesized by a variety of methods including, for example, the following methods:

[0088] (a) a method for isolating and purifying the final peptide product after synthesizing the peptide by stepwise or fragment assembly by means of a solid or liquid method; or (b) a method for recovering the expression product from the host cell culture after expressing a nucleic acid construct encoding the peptide in a host cell; or (c) a method for recovering the expression product after expressing a nucleic acid construct encoding the peptide in a cell-free laboratory; or a method for recovering the relevant peptide by obtaining peptide fragments by any combination of (a), (b) and (c), and then obtaining the peptide by connecting the fragments.

[0089] In one embodiment, the present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a conjugate of melittin, its variants or their analogs combined with a pro-apoptotic peptide or an anticancer agent as an effective ingredient.

[0090] In one example, the cancer can be selected from brain tumors, melanoma, myeloma, non-small cell lung cancer, oral cancer, liver cancer, stomach cancer, colon cancer, breast cancer, triple negative breast cancer (Triple Negative Breast Cancer, TNBC), lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cervical cancer, ovarian cancer, colorectal cancer, small intestine cancer, rectal cancer, fallopian tube cancer, perianal cancer, endometrial cancer, vaginal cancer, vulvar cancer, Hodgkin's disease (Hodgkin's disease), esophageal cancer, lymph node cancer, bladder cancer, gallbladder cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, kidney or ureteral cancer, renal cell carcinoma, renal pelvis cancer, central nervous system tumor, primary central nervous system lymphoma, spinal cord tumor, brain stem glioma and pituitary adenoma. One or more of the group consisting of can be anticancer drug-resistant cancer.

[0091] In one embodiment, the composition can be administered to a patient in which the expression of ITGB2 in M2 macrophages is upregulated compared with the expression in M0 macrophages and M1 macrophages.

[0092] In one example, the above composition can be a targeted anti-cancer agent.

[0093] The pharmaceutical composition of the present invention can be used as a single treatment method or used together with other common biological therapies, chemotherapy or radiotherapy. When such a combination therapy is implemented, cancer can be treated more effectively. When the present invention is used in the prevention and treatment of cancer, the chemotherapeutic agents that can be used together with the above composition include cisplatin, carboplatin, procarbazine, mechlorethamine, cyclophosphamide, ifosfamide, melphalan, Lun (melphalan), chlorambucil, busulfan, nitrosourea, dactinomycin, Daunorubicin, doxorubicin, bleomycin, plicomycin, mitomycin C, etoposide, tamoxifen, taxol, transplatinum, 5-fluorouracil, vincristine, vinblastine and methotrexate, etc. Radiotherapy that can be used together with the composition of the present invention is X-ray irradiation and gamma ray irradiation.

[0094] In the present invention, the term "prevention" refers to all actions to inhibit or delay the occurrence, spread and recurrence of cancer by administering the composition of the present invention.

[0095] The therapeutically effective amount of the composition of the present invention may vary depending on a variety of factors, such as the method of administration, the target site, the patient's condition, etc. Therefore, when administered to the human body, the dosage should be determined by considering both safety and effectiveness. The amount used in humans can be deduced from the effective amount determined by animal experiments. Matters to be considered when determining the effective amount are described in, for example, Hardman and Limbird, eds., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. (2001), Pergamon Press; and EWMartin ed., Remington's Pharmaceutical Sciences, 18th ed. (1990), Mack Publishing Co.

[0096] The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" used in the present invention refers to an amount that is sufficient and does not cause side effects to treat a disease at a reasonable benefit / risk ratio that can be applied in medical treatment, and the effective dose level is determined based on factors including the patient's health status, the type of disease, the severity, the activity of the drug, the sensitivity to the drug, the method of administration, the time of administration, the route of administration and the metabolic ratio, the treatment period, the drugs used in conjunction or simultaneously, and other factors well known in the medical field. The composition of the present invention can be administered as a single therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with existing therapeutic agents. The key point is that after all the above factors are considered, the amount of the maximum effect is obtained with the minimum amount that does not cause side effects, which can be easily determined by a person of ordinary skill in the art to which the present invention belongs.

[0097] The pharmaceutical composition of the present invention may include a carrier, a diluent, an excipient or a combination of two or more of the carriers commonly used in biological preparations. The term "pharmaceutically acceptable" used in the present invention refers to a property that exhibits no toxicity to normal cells or humans exposed to the above-mentioned composition. The above-mentioned carrier is not particularly limited as long as it is suitable for delivering the composition into the body. For example, the compound recorded in Merck Index, 13th ed., Merck & Co. Inc., physiological saline, sterile water, Ringer's solution, buffered physiological saline, glucose solution, maltodextrin solution, glycerol, ethanol and a mixture of one or more of the above-mentioned components can be used, and other common additives such as antioxidants, buffers, sterilizers, etc. can also be added as needed. In addition, it can also be prepared into an injection dosage form, pills, capsules, granules or tablets such as an aqueous solution, a suspension, an emulsion, etc. by adding a diluent, a dispersant, a surfactant, a binder, and a lubricant. Furthermore, the drug can be preferably formulated according to each disease or component using an appropriate method in the technical field to which the present invention pertains or a method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).

[0098] In one example, the pharmaceutical composition can be in one or more dosage forms selected from the group consisting of oral dosage forms, external preparations, suppositories, sterile injection solutions, and sprays.

[0099] The composition of the present invention may include a carrier, a diluent, an excipient or a combination of two or more of the carriers commonly used in biological preparations. Pharmaceutically acceptable carriers are not particularly limited as long as they are suitable for delivering the composition in vivo. For example, compounds recorded in Merck Index, 13th ed., Merck & Co. Inc., saline, sterile water, Ringer's solution, buffered saline, glucose solution, maltodextrin solution, glycerol, ethanol and one or more of the above components can be used, and antioxidants, buffers, sterilizers and other common additives can also be added as needed. In addition, it can also be prepared into injection dosage forms such as aqueous solutions, suspensions, emulsions, pills, capsules, granules or tablets by adding diluents, dispersants, surfactants, binders, and lubricants. Furthermore, it can be preferably prepared according to each disease or component using the appropriate method in the technical field of the present invention or the method disclosed in Remington's Pharmaceutical Science (Mack Publishing Company, Easton PA, 18th, 1990).

[0100] The composition of the present invention may also include one or more active ingredients showing the same or similar functions. Relative to the total weight of the composition, the composition of the present invention comprises 0.0001 to 10 weight percent of the above protein, preferably, 0.001 to 1 weight percent of the above protein.

[0101] The pharmaceutical composition of the present invention may further include pharmaceutically acceptable additives, in which case, the pharmaceutically acceptable additives may include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, starch syrup, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, white sugar, glucose, sorbitol, talc, etc. Preferably, relative to the above composition, the pharmaceutically acceptable additives of the present invention may be included in an amount of 0.1 to 90 parts by weight, but are not limited thereto.

[0102] The composition of the present invention can be administered parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically) or orally according to the intended method, and the dosage range can vary according to the patient's weight, age, sex, health status, diet, administration time, administration method, metabolic rate, and severity of the disease. The daily dosage of the composition of the present invention is 0.0001 mg / ml to 10 mg / ml, preferably 0.0001 mg / ml to 5 mg / ml, and more preferably, once a day or divided into several doses.

[0103] Liquid preparations for oral administration of the composition of the present invention include suspensions, internal solutions, emulsions, syrups, etc., which may contain, in addition to water and liquid paraffin, which are usually used as simple diluents, a variety of excipients, such as wetting agents, sweeteners, aromatics, preservatives, etc. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, oils, freeze-dried preparations, suppositories, etc.

[0104] In one embodiment, the present invention relates to a method for removing M2 tumor-associated macrophages, comprising the step of treating the composition of the present invention to M2 tumor-associated macrophages in the laboratory.

[0105] In one embodiment, the present invention relates to a composition for cancer diagnosis comprising the composition of the present invention.

[0106] In one embodiment, the present invention relates to a cancer diagnosis kit comprising the cancer diagnosis composition of the present invention.

[0107] The term "cancer diagnosis kit" of the present invention refers to a kit comprising a composition for cancer diagnosis of the present invention. Therefore, the expression of the above-mentioned "cancer diagnosis kit" can be used interchangeably or mixed with "cancer diagnosis composition". The term "diagnosis" in this specification includes judging the sensitivity (susceptibility) of an individual to a specific disease or illness, judging whether an individual currently suffers from a specific disease or illness, judging the prognosis (prognosis) of an individual suffering from a specific disease or illness (e.g., identification of pre-metastatic or metastatic cancer status, determination of the stage of cancer, or determination of the responsiveness of cancer to treatment) or treatment metrics (therametrics) (e.g., simulating the state of an individual in order to provide information about the efficacy of treatment).

[0108] The melittin, its variants or their analogs of the present invention specifically bind to ITGB2 expressed on the cell membrane of M2 tumor-associated macrophages to enable themselves or drugs (pro-apoptotic peptides or anticancer agents) connected to them to kill M2 tumor-associated macrophages, thereby inhibiting tumor growth and metastasis, and have anticancer activity by selectively inhibiting surrounding angiogenesis. Since they specifically bind to M2 tumor-associated macrophages, they can also be used as therapeutic diagnostic preparations in the diagnosis of cancer. In addition, they can also be used as anticancer adjuvants administered together with anticancer agents, alone or in sequence. At the same time, since melittin, its variants or their analogs specifically bind to M2 tumor-associated macrophages, they can also be used as drug carriers targeting them.

[0109] In one embodiment, the present invention relates to a method for providing information for cancer diagnosis, comprising: a step of contacting a biological sample isolated from a subject with the composition of the present invention; and a step of comparing with a sample of a normal control group.

[0110] In one example, the method may further include the step of: if the level of M2 tumor-associated macrophages in the biological sample separated from the subject is higher than that in the sample of the normal control group, determining that the subject is suffering from cancer.

[0111] The term "specimen" used in the present invention refers to a biological sample obtained from a subject or patient. The supply source of the biological sample can be: solid tissue derived from fresh, frozen and / or preserved organ or tissue samples or biopsies or aspirates; blood or any blood component; cells at any time point of pregnancy or development of the subject.

[0112] In one embodiment, the present invention relates to a method for treating cancer, comprising administering a conjugate of melittin, its variants or their analogs combined with a pro-apoptotic peptide or an anti-cancer agent of the present invention to an individual suffering from cancer in a pharmaceutically effective amount.

[0113] In one example, the individual may be a patient in which the expression of ITGB2 in M2 macrophages is upregulated compared with the expression in M0 macrophages and M1 macrophages.

[0114] In one embodiment, the present invention relates to the use of a conjugate of melittin, its variants or their analogs combined with a pro-apoptotic peptide or an anti-cancer agent in the preparation of a pharmaceutical composition for preventing and treating cancer.

[0115] The present invention will be described in more detail by the following examples. However, the following examples are only used to specify the contents of the present invention, and the present invention is not limited to these examples. DETAILED DESCRIPTION

[0117] Example 1. Synthesis of M2 tumor-associated macrophage (M2 TAM) targeting peptides

[0118] Melittin and TAMpep826 shown in Table 1 below were obtained by commissioning synthesis from GenScript (Piscataway, NJ, USA), and dissolved in D-PBS at a concentration of 5 mg / ml for use in subsequent experiments.

[0119] Table 1

[0120]

[0121] Example 2. M2 TAM targeting analysis

[0122] 2-1. Confirmation of the affinity of melittin for M2 TAM

[0123] In order to confirm whether the melittin prepared in the above Example 1 specifically binds to M2 tumor-associated macrophages (M2 TAMs), human monocytic cell line THP-1 was differentiated into M0, M1 and M2 macrophages, and then treated with FITC-coupled melittin and confirmed by flow cytometry. Specifically, THP-1 cells were treated with 100 nM phorbol 12-myristate 13-acetate (PMA) at 37°C for 24 hours (M0 macrophages), and then the differentiated M0 macrophages were cultured with 100 nM LPS and 20 ng / ml IFN-γ at 37°C for 72 hours to differentiate into M1 macrophages (M1), and cultured with 20 ng / ml IL-4 and IL-13 at 37°C for 72 hours to differentiate into M2 macrophages (M2). After the differentiated cells were treated with 50 nM FITC-conjugated melittin for 1 hour, the cells were detected using BD FACSCantoII instruments (BD biosciences, San Jose, CA, USA) and analyzed using FlowJo software (BD biosciences).

[0124] The results showed that compared with M0 and M2 macrophages, the number of FITC-positive cells in M2 macrophages increased significantly ( Figure 1a and Figure 1b ). This confirmed that melittin preferentially binds to M2 macrophages.

[0125] 2-2. M2 TAM binding target protein recognition of melittin

[0126] In order to confirm which protein of M2 macrophages is related to the specific binding of melittin to M2 macrophages, biotin-conjugated melittin (melittin-biotin) was synthesized. 6After cells were differentiated into M0, M1 and M2 macrophages, the cells were collected with a scraper and washed by centrifugation (300×g, 5 minutes) and then the membrane protein of the macrophages was obtained using a membrane protein extraction kit (ThermoFisher scientific). After reacting with melittin-biotin (200 μg) bound to biotin at room temperature (20-24°C) for 1 hour, the protein bound to melittin was obtained using streptavidin resin (ThermoFisher). In order to remove salts, 100 μl of 100% ethanol, 0.1% formic acid and 80% CAN were added to a 18 Micro Spin-Column to prepare it, and after loading the sample on the prepared column, 50 μl of 0.1% formic acid was added to remove unnecessary substances. Then, 100 μl of 80% CAN was added to elute the peptide. After desalting, Speed-vac was used to dry the solution to completely remove it, and the solution was analyzed by LC-MS / MS using a UPLC-Exactive instrument (Thermo Fisher Scientific) under the conditions of Table 2 below. Data analysis was performed on proteins upregulated in M1 and M2 macrophages relative to M0 macrophages using MaxQuant and MPP (Mass Profiler Professional). For data analysis, Proteome Discoverer was used to analyze LC-MS / MS data at different time scales, and the database used the human database of Uniprot, and label-free quantification (LFQ, Label-Free Quantification) was performed. Modifications added oxidation (Oxidation) (M), carbamylation (Carbamyl) (N-term) and carbamidomethyl (Carbamidomethyl) (C), and the baseline option was none (none).

[0127] Table 2

[0128]

[0129]

[0130] As a result, 53 proteins were up-regulated in M2 / M0 and 123 proteins were up-regulated in M1 / M0 ( Figure 2a). Although more upregulated proteins interact with M1 macrophages than M2 macrophages, this is not the case for proteins present in the cell membrane. Among membrane proteins, ITGB2 was shown to be upregulated in M2 macrophages ( Figure 2b ). In addition, cytokines such as IL-10 and CXCL10, which are known markers of M1 macrophages, were upregulated in M1 macrophages (Figure 2v). In addition, although proteins that were upregulated in M2 compared to M1 were confirmed, only ITGB2 was confirmed to be upregulated in M2 macrophages among membrane proteins ( Figure 2d ). This confirmed that melittin interacts and binds to the membrane protein ITGB2 of M2 macrophages.

[0131] 2-3. M2 TAM binding target protein recognition by TAMpep826

[0132] In the same manner as in Example 2-2, cell membrane proteins extracted from M0, M1, and M2 macrophages were reacted with TAMpep826-biotin, and the target protein was confirmed by LC-MS / MS proteomics.

[0133] As a result, among the cell membrane proteins, ITGB2 was shown to be expressed at a higher level in M2 macrophages compared to M0 and M1 macrophages ( Figure 4 ), TAMpep826 was identified as a binding target protein of M2 macrophages.

[0134] Example 3. Confirmation of ITGB2 expression in M2 macrophages

[0135] 3-1. Confirmation of ITGB2 mRNA expression

[0136] In order to evaluate the mRNA expression level of ITGB2 in M0, M1, M2 macrophages and TAMs, real-time polymerase chain reaction was performed. Specifically, RNA was extracted from cells differentiated into M0, M1 or M2 macrophages using the easy-BLUE total RNA Extraction Kit (iNtRON), and cDNA was synthesized using CycleScript-Reverse Transcriptase (Bioneer). Primers for Actin or ITGB2 genes (Table 3) were used and the expression of Figure 5 Real-time polymerase chain reaction (real-time PCR) (CFX96, Bio-rad) was performed under the conditions to compare and analyze the expression level of each gene relative to Actin by relative quantification.

[0137] Table 3

[0138]

[0139]

[0140] The results showed that the mRNA expression of ITGB2 was significantly increased in M2 macrophages and TAMs compared with M0 and M1 macrophages ( Figure 6 ).

[0141] 3-2. Confirmation of ITGB2 protein expression

[0142] Western blot analysis was performed to evaluate the protein expression level of ITGB2 in M0, M1, M2 macrophages and TAMs. Specifically, proteins were extracted from cells differentiated into M0, M1 and M2 macrophages using Proprep solution (iNtRON) and transferred to the membrane using electrophoresis. The membrane was blocked by soaking in 5% bovine serum albumin (BSA), treated with primary antibody (ITGB2) at 4°C for 24 hours, treated with secondary antibody at room temperature for 1 hour, and treated with D-Plus TM ECL Pico System (Dongren LS Co., Ltd.) and then used Davinch-Chemi TM The protein bands were photographed using an imaging system (Intoxia).

[0143] The results showed that the protein expression of ITGB2 was significantly increased in M2 macrophages and TAMs compared with M0 and M1 macrophages ( Figure 7 ).

[0144] 3-3. Confirmation of ITGB2 protein expression by immunofluorescence

[0145] In order to evaluate the protein expression level of ITGB2 in M0, M1, M2 macrophages and TAMs, immunofluorescence analysis was performed. Specifically, each cell differentiated into M0, M1 and M2 macrophages was fixed with 4% formalin, washed with PBS and immersed in 5% BSA for blocking, and then treated with primary antibody (ITGB2) at 4°C for 24 hours and secondary antibody at room temperature for 2 hours. After DAPI-stained cells were counted (mounting), fluorescent photos were taken using LSM800 (Zeiss).

[0146] The results showed that the expression level of ITGB2 protein was higher in M2 macrophages and TAMs than in M0 and M1 macrophages ( Figure 8 ).

[0147] Example 4. Confirmation of the interaction between M2 TAM targeting peptide and ITGB2

[0148] 4-1. Confirmation of ITGB2 expression on the cell membrane of M2 macrophages

[0149] In order to confirm whether ITGB2 is expressed in the cell membrane of M2 macrophages, cell membrane proteins and cytosol proteins were isolated and extracted from M2 macrophages, respectively, and then reacted with biotinylated TAMpep826 and evaluated by Western blot analysis. The results showed that ITGB2 protein was expressed in the cell membrane of M2 macrophages ( Fig. 9 ).

[0150] 4-2. Confirmation of the interaction between TAMpep826 and ITGB2

[0151] In order to confirm whether TAMpep826 interacts with ITGB2 in M2 macrophages, the expression of ITGB2 was evaluated by a competitive reaction between TAMpep826 and biotinylated TAMpep826. Specifically, cells differentiated into M2 macrophages were collected using a scraper and washed by centrifugation (300×g, 5 minutes), and then the cell membrane proteins of macrophages were obtained using a cell membrane protein extraction kit (Thermo Fisher Scientific). TAMpep826 or scramble peptide was pretreated for 1 hour at different concentrations (0.001μg, 0.01μg, 0.1μg, 1μg and 10μg), and then reacted with biotin-bound TAMpep826 (200μg) at room temperature (20-24°C) for 1 hour using Dynabeads. TM M-280 streptavidin (Thermo Fisher Scientific) was used to obtain proteins bound to TAMpep826. Proteins were analyzed by Western blotting to confirm the expression of ITGB2.

[0152] The results showed that when the scrambled peptide was pretreated, the expression of ITGB2 bound to biotinylated TAMpep826 was not affected. On the contrary, when TAMpep826 was pretreated, the expression of ITGB2 was inhibited as the concentration increased ( Fig.10 ). This confirmed that TAMpep826 interacts with ITGB2 in the cell membrane of M2 macrophages.

[0153] 4-3. Confirmation of the interaction between TAMpep826 and ITGB2 by immunofluorescence

[0154] In order to confirm whether ITGB2 and TAMpep826 co-localize in the cell membrane of M2 macrophages, immunofluorescence analysis was performed using TAMpep826 conjugated with FITC. The results showed that TAMpep826 and ITGB2 were concentrated in the cell membrane of M2 macrophages ( Fig.11 ).

[0155] 4-4. Confirmation of the binding site between TB511 and ITGB2

[0156] Based on the sequence of the cysteine-rich part of CD18 (ITGB2) (uniport_p05107, Cystein-rich tandem repeats region: 449-617), the tertiary structure was constructed using the trRosetta algorithm (https: / / yanglab.nankai.edu.cn / trRosetta / ). Then, the docking simulation of TB511 and CD18 was implemented using the CABS-dock server (http: / / biocomp.chem.uw.edu.pl / CABSdock / ) with the CD18 PDB file produced by trRosetta and the amino acid sequence of TB511. Among the 10 models obtained from the docking simulation results, the representative model was selected based on the alanine substitution results of the TB511 sequence ( Fig.12 ).

[0157] As a result, it was predicted that LEU (6) of TB511 would bind to the LEU (528), THR (538), LEU (556), CYS (557) and PHE (558) sites of CD18, and it was predicted that TRP (12) of TB511 would bind to GLU (466), ILE (469), CYS (470) and ARG (471) of CD18. Furthermore, when LEU (6) and TRP (12) of TB511 were replaced with alanine to simulate binding with CD18, it was shown that both sites did not bind to any sequence of CD18. Therefore, it was predicted that LEU (6) and TRP (12) of TB511 were the core parts of the docking between TB511 and CD18, and it could be predicted that TB511 would bind to sites 466 to 565 of CD18 ( Fig.13 ).

[0158] Example 5. Synthesis of ITGB2 binding moieties

[0159] 5-1. Synthesis of ITGB2-binding PDC (peptide-drug conjugate)

[0160] After commissioning synthesis from GenScript (Piscataway, New Jersey, USA), the bee venom peptide-dKLA and TB511 peptides shown in Table 4 were obtained and dissolved in D-PBS at a concentration of 5 mg / ml for use in subsequent experiments. dKLA is linked via an amide bond between peptides. In order to minimize the interaction and folding between bee venom peptide or TAMpep826 and dKLA, a linker consisting of 4 glycines and 1 serine is set in the middle to distinguish the two ends. In order to minimize in vivo decomposition, KLA uses the D-isomer instead of the L-isomer. Furthermore, in order to prepare M-DM1, maleimide-modified bee venom peptide (GenScript, Beijing, China) (100 μM, 1 mL, 0.1 mmoL) dissolved in 25 mM sodium borate buffer (25 mM sodium chloride (NaCl), 1 mM ethylenediaminetetraacetic acid (EDTA), pH 8.0) was added with DM1 (Mertansine) (MedChem Express, Princeton) (1.1 equivalents, 10 mM in DMF) and DMF (dimethylformamide) and reacted at 37° C. for 1 hour, and the resultant was filtered three times by ultrafiltration in Dulbecco's phosphate buffered saline (DPBS; Welgene), thereby preparing PDC by binding DM1 to the N-terminus of maleimide-modified bee venom peptide M, and it was named M-DM1. The prepared M-DM1 was injected into a reverse phase high performance liquid chromatograph (HPLC) at a flow rate of 5 μL and 0.5 mL / min in a Poroshell 120C18 column (2.7 μm, 3×50 mm, Agilent, Santa Clara, CA, USA) to analyze the properties.

[0161] Table 4

[0162]

[0163] 5-2. Synthesis of ITGB2-binding ADC (Antibody-drug conjugate)

[0164] 5-2-1. Preparation of ADCs of anti-CD18 antibody and DM1

[0165] In order to prepare an antibody that specifically binds to the active conformation of CD18, which is one of the macrophage-1 antigens (Mac-1), in M2 TAMs ( Fig.14), collect the culture fluid of hybridoma (MM18 / 2.a.8) cells secreting anti-CD18 antibodies, centrifuge at 2500rpm at 4°C for 10 minutes to obtain the supernatant, and then purify it by protein G-agarose column chromatography. The antibody solution is slowly passed through a protein G-agarose column (Pharmacia, Sweden) pre-equilibrated with PBS, and the column is connected to a peristaltic pump and washed thoroughly with PBS. After washing, the antibody is eluted with 0.2M glycin-HCl (pH 2.7). In this case, the eluate is buffered in a test tube containing 1M Tris (pH 9.0) prepared in advance. The antibody is used after dialysis in PBS. Using a BCA protein analysis kit (BCA TM Protein Assay Kit, Pierce) was used to measure the amount of purified antibody, and the binding ability of the antibody was confirmed by flow cytometry analysis. After the buffer was replaced with PBS (pH 7.4) for anti-CD18 antibody, SMCC-DM1 (mertansine, 120 μM) (MedChemExpress) dissolved in dimethyl sulfoxide (DMSO) was mixed with anti-CD18 antibody (1 mg / ml, 6.67 μM) at a ratio of 1:18 and reacted at room temperature for 4 to 20 hours. In order to remove unreacted DM1, PBS (pH 7.4) was used to replace the buffer for anti-CD18-DM1 using a 10KDa cutoff centrifugal filter, and then filtered using a 0.2 μm syringe filter. The amount of DM1 (252 nM) bound to the anti-CD18 antibody (280 nM) was measured by UV-Vis spectroscopy to calculate the ratio of DM1 to the anti-CD18 antibody (DAR), and the DAR value was 5.8. The ADC prepared in this way in which the anti-CD18 antibody and DM1 were bound was named CD18-DM1.

[0166] 5-2-2. Preparation of ADCs of anti-CD18 antibodies and MMAE (monomethyl auristatin E)

[0167] After the anti-CD18 antibody purified in the above example was buffer exchanged with PBS (pH 7.4), in order to partially reduce the disulfide bond of the CD18 antibody, 1 mM DTT (66.7 μM) was mixed with the anti-CD18 antibody (1 mg / ml, 6.67 μM) at a ratio of 1:10, reacted at 37°C for 1 to 2 hours, and then the buffer was exchanged with PBS (pH 7.4). 10 mM Suo-Val-Cit-PAB-MMAE (MedChemExpress) was mixed with the partially reduced anti-CD18 antibody (1 mg / ml, 6.67 μM) at a ratio of 1:20 to 1:40, reacted at 4°C for 12 hours, and then the buffer was exchanged with PBS (pH 7.4). The amount of vc-MMAE (248 nM) bound to anti-CD18 antibody (280 nM) was measured by UV-Vis spectrometer to calculate the ratio of vc-MMAE to anti-CD18 antibody (Drug antibody ratio, DAR), and the DAR value was shown to be 2.8 to 5.4. The ADC in which the anti-CD18 antibody prepared in this way is bound to MMAE is named CD18-MMAE.

[0168] Example 6. Confirmation of ITGB2 binding to M2 TAM binding of PDC

[0169] In order to confirm the binding force between ITGB2 and melittin-dKLA, the ITGB2 protein was fixed on a golden thin film sensor chip, and the ITGB2 antibody and melittin-dKLA as a positive control group were flowed through to measure the reflected light, and then surface plasmon resonance (SPR) analysis was performed. Specifically, after ITGB2 was fixed on the surface of the sensor chip, it was immobilized using amine coupling under the conditions of Table 5 below ( Fig.15 Then, various concentrations of ITGB2 antibody and melittin-dKLA were passed through the ITGB2-coated sensor to observe the association and dissociation intervals, and the intermolecular binding rate constant (kinetic constant (kinetic prarmeter)) was calculated from the sensorgram using the intermolecular binding rate constant analysis (kinetic evaluation (kinetic evoluation)) conditions in Table 6 below.

[0170] Table 5

[0171]

[0172] Table 62) Kinetic evaluation

[0173]

[0174]

[0175] As a result, the equilibrium dissociation constant (KD) obtained by dividing the dissociation rate constant (kd) of the binding force between two molecules of the ITGB2 antibody as a positive control group by the association rate constant (ka) was 1.14. -8 The equilibrium dissociation constant of melittin-dKLA is shown to be 7.86 -8 ( Fig.16 and Fig.17 ). Therefore, it was confirmed that melittin-dKLA has binding ability with ITGB2.

[0176] Example 7. Confirmation of the apoptotic effect of ITGB2 on M2 TAM cells via PDC

[0177] 7-1. Preparation of ITGB2 expression inhibition cell model

[0178] As a cell model for confirming whether ITGB2 induces apoptosis in M2 macrophages, a cell model for inhibiting ITGB2 expression in M2 macrophages was prepared using Crispr / cas9. Specifically, cells differentiated into M2 macrophages were cultured in Opti-MEM medium. Crispr / cas9 is a cell model for inducing apoptosis in M2 macrophages by inserting CRISPRMAX TM Cas9 protein V2 (Thermo Fisher Scientific) and gRNA (Genscript; ITGB2; Table 7) of the Reagentkit (Thermo Fisher Scientific) and Cas9 Plus TM Reagent (Thermo Fisher Scientific) was mixed together and CRISPRMAX TM The reagent was diluted in Opti-MEM medium and mixed to react for 5-10 minutes, then added to the cells differentiated into M2 macrophages and cultured at 37° C. for 2-3 days. Then, the mRNA expression level of ITGB2 was confirmed.

[0179] Table 7

[0180]

[0181] The results showed that the expression of ITGB2 in M2 macrophages injected with ITGB2 sgRNA was significantly reduced compared with the control group ( Fig.18 ).

[0182] 7-2. Confirmation of M2 TAM cell apoptosis by melittin-dKLA-mediated ITGB2

[0183] In order to confirm whether bee venom peptide-dKLA binds to ITGB2 in M2 macrophages to induce apoptosis, bee venom peptide-dKLA (1 μM) was treated for 24 hours to M2 macrophages in which ITGB2 expression was inhibited by Crispr / cas9 prepared in Example 7-1 above, and the cell survival rate was analyzed by CCK-8 analysis. Specifically, bee venom peptide-dKLA (1 μM) was reacted to ITGB2 knockdown macrophages prepared in Example 7-1 above for 1 hour. After the reaction, the culture medium was replaced and cultured at 37°C for 24 hours. In order to confirm the cell viability, 1 / 10 of the CCK-8 reagent (EnzoLife Sciences) was placed in the culture medium and reacted at 37°C for 3 hours. The absorbance was measured at a wavelength of 450nM using a microplate reader (Molecular Devices).

[0184] As a result, the cell survival rate of M2 macrophages in the control group was significantly reduced by melittin-dKLA, but the reduction of cell survival rate by melittin-dKLA was suppressed in M2 macrophages with ITGB2 knockdown ( Fig.19 ). Therefore, it was confirmed that melittin-dKLA induces apoptosis of M2 macrophages by specifically binding to ITGB2 of M2 macrophages.

[0185] 7-3. Confirmation of TB511-induced apoptosis of M2 TAM cells via ITGB2

[0186] In order to confirm whether TB511 (TAMpep826-dKLA) induces apoptosis in M2 macrophages through ITGB2, the M2 macrophages in which ITGB2 expression was inhibited by Crispr / cas9 prepared in Example 7-1 were reacted with TB511. The results showed that M2 macrophages showed about 50% cell viability by TB511, but in cells in which ITGB2 expression was inhibited, cell viability was significantly increased ( Fig. 20 ).

[0187] 7-4. Confirmation of reduction of apoptosis induction in TB511 cells by ITGB2 antibody

[0188] In order to determine whether TB511 induces apoptosis in M2 macrophages through ITGB2, the M2 macrophages prepared in the above Example 7-1 for inhibiting ITGB2 expression were pretreated with anti-ITGB2 antibody (polyclonal rabbit anti-human ITGB2 / CD18 antibody) (LS-C312785; LS Bio) (1 μg) for 1 hour and reacted with TB511 (1 μM) for 1 hour. Then, the induction of apoptosis was confirmed by cell viability analysis using CCK-8 analysis, the protein expression of caspase-3, a cell apoptosis marker, was confirmed by Western blotting analysis, the gene expression of caspase-3, caspase-8, and caspase-9 was confirmed by real-time polymerase chain reaction, and the induction of caspase-3 protein expression was confirmed by immunofluorescence.

[0189] As a result, the cell viability of M2 macrophages was not affected by ITGB2 antibody, but was significantly reduced by TB511. In contrast, in M2 macrophages pretreated with ITGB2 antibody, the cell viability was significantly increased by TB511 ( Fig.21 ). In addition, TB511 significantly increased the expression of caspase-3 in M2 macrophages, whereas TB511 significantly reduced the expression of caspase-3 in M2 macrophages pretreated with ITGB2 antibodies ( Fig.21 ). In addition, the expression of caspase-3, caspase-8, and caspase-9 in M2 macrophages was significantly increased by TB511. On the contrary, the expression of caspase-3, caspase-8, and caspase-9 in M2 macrophages pretreated with ITGB2 antibody was significantly reduced by TB511 ( Fig.21 ). TB511 significantly increased the expression of caspase-3 in M2 macrophages. Conversely, TB511 reduced the expression of caspase-3 in M2 macrophages pretreated with ITGB2 antibodies ( Fig.21 ). In addition, the results of confirming that TB511 targets mitochondria showed that the coexistence of mitochondria and TB511 decreased in M2 macrophages pretreated with ITGB2 antibodies compared with cells not pretreated with ITGB2 ( Fig.21 ).

[0190] Example 8. Confirmation of the efficacy of PDCs in three-dimensional cancer organoids

[0191] 8-1. Confirmation of the effect of TB511 in breast cancer 3D organoids

[0192] In order to correct the critical point in vitro and then replace it in vivo, a three-dimensional organoid was prepared to simulate the cancer microenvironment (TME) of breast cancer and confirm the effect of TB511 on it. Specifically, after mixing matrigel at a concentration of 3% with RPMI-1640 culture medium, MDA - MB-231 human breast cancer cells, cancer-associated fibroblasts (CAF) and Nuclight Lentivirus Reagents (Sartorius) were used to count THP-1 cells prepared to express GFP, and then 200 μl was dispensed into a 96-well u-bottom 3-D culture plate at a ratio of 5:1:1. After culture, the cells were collected by centrifugation at 1200 rpm for 3 minutes, and then cultured in a 37°C incubator for 48 hours to form spheroids. Starting from the second day after spheroid formation, TB511 was treated at concentrations of 1 μM, 2 μM, 4 μM, and 8 μM every three days, and images were taken using a fluorescence microscope. After taking bright-field images, the diameter of the particles was measured by a measurement method to measure the spheroid area. In addition, after measuring 3 diameters for each sphere using open source, the size of the average tumor rotation ellipse diameter was analyzed by ImageJ (software version 1.47m), and after taking bright field images (20X), the sphere size was analyzed by ImageJ (software version 1.47m) after measuring 3 average tumor rotation ellipsoid diameters for each sphere. At the same time, after fixing the spheres on the 10th day of drug treatment, they were reacted with antibodies to ki-67 (abcam), a tumor growth factor, for immunofluorescence staining (control staining: DAPI). In the case of THP-1, no additional staining was performed, and the GFP fluorescence expressed in the cells was photographed using a confocal microscope and the number of cells expressing fluorescence was measured.

[0193] The results showed that the size of the spheres in the group without drug treatment gradually increased over time, and THP-1 cells, which are monocytes, promoted tumor growth by differentiating into TAMs through cancer cells and TME when cancer cells and CAFs were co-cultured. In contrast, in the group treated with TB511, it was confirmed that the size of the spheres decreased in a concentration-dependent manner starting from a concentration of 1 μM on day 10 ( Fig. 22), compared with the drug-free group, the number of THP-1 cells expressing GFP fluorescence was significantly reduced in a concentration-dependent manner ( *** p<0.001)( Fig.23 ). Thus, it was confirmed that TB511, an ITGB2-binding PDC, induces apoptosis of MDA-MB-231 human breast cancer cells by selectively binding to THP-1 cells.

[0194] 8-2. Confirmation of the effect of TB511 in lung cancer 3D organoids

[0195] After A549 human lung cancer cells, CAF and THP-1 cells were mixed by the method of Example 8-1 to prepare lung cancer three-dimensional spheroids, TB511 was treated at concentrations of 1 μM, 2 μM and 4 μM, respectively, and the effect was analyzed by the same method as in Example 8-1. When preparing spheroids, three-dimensional spheroids were prepared using cancer cells alone or only cancer cells + CAF cells were mixed to compare the size of the spheroids.

[0196] The results showed that the size of spheres formed with A549+CAF+THP-1 cells increased significantly compared with the case of spheres formed with A549 cells alone or A549+CAF cells alone. In addition, the size of spheres in the TB511-treated group decreased significantly depending on the TB511 concentration compared with the group not treated with TB511 ( *** p<0.001)( Fig.24 ). In addition, the results of fluorescent staining of the spheroids to confirm the results of related markers on the 10th day after drug treatment showed that the number of THP-1 cells was significantly reduced in a concentration-dependent manner compared to the group not treated with TB511, and the tumor growth factor ki-67 was also reduced in a concentration-dependent manner ( *** p<0.001)( Fig.25 ).

[0197] 8-3. Confirmation of the effect of M-DM1 in lung cancer 3D organoids

[0198] In order to confirm the efficacy of M-DM1 (Mel-DM1) against lung cancer, A549 human lung cancer cells, CAF and THP-1 cells were mixed by the method of Example 8-1 to prepare lung cancer 3D spheroids, and then M-DM1 was treated at concentrations of 1 μM, 2 μM and 4 μM, respectively, and its effect was analyzed by the same method as Example 8-1.

[0199] The results showed that the size of spheres in the M-DM1 treated group decreased in a concentration-dependent manner compared with the M-DM1 untreated group ( *** p<0.001)( Fig.26 ).

[0200] Example 9. Confirmation of the efficacy of PDC in three-dimensional cancer organoids resistant to anticancer agents

[0201] 9-1. Confirmation of the effect of TB511 in three-dimensional organoids of lung cancer resistant to anticancer drugs

[0202] In order to confirm the efficacy of TB511 against carboplatin-resistant lung cancer, carboplatin-resistant A549 cells, CAF and THP-1 cells were mixed by the method of Example 8-1 to form three-dimensional spheres, and then TB511 was treated at concentrations of 1 μM, 2 μM and 4 μM, respectively, and its effect was analyzed by the same method as Example 8-1.

[0203] The results showed that the size of spheres formed by A549+CAF+THP-1 cells was significantly increased compared with the case of spheres formed by A549 resistant cells alone or A549+CAF cells alone. The size of spheres in the TB511 treated group was significantly reduced in a TB511 concentration-dependent manner compared with the group not treated with TB511 ( *** p<0.001)( Fig. 27 ). In addition, the results of fluorescent staining of the spheroids to confirm the results of related markers on the 10th day after drug treatment showed that the number of THP-1 cells in the TB511-treated group was significantly reduced in a concentration-dependent manner compared to the group not treated with TB511, and the tumor growth factor ki-67 also decreased significantly starting from a concentration of 2μM ( *** p<0.001)( Fig.28 ).

[0204] 9-2. Confirmation of the effect of TB511 in three-dimensional organoids of prostate cancer resistant to anticancer drugs

[0205] In order to confirm the efficacy of TB511 against docetaxel-resistant prostate cancer, docetaxel-resistant PC3 prostate cancer cells, CAFs and THP-1 cells were mixed by the method of Example 8-1 to form three-dimensional spheres, and then TB511 was treated at a concentration of 1 μM, 2 μM or 4 μM, respectively, and its effect was analyzed by the same method as Example 8-1.

[0206] The results showed that the size of spheroids formed by PC3+CAF+THP-1 cells was significantly increased compared with the case of spheroids formed by PC3 resistant cells alone or PC3+CAF cells alone. Compared with the group not treated with TB511, the size of spheroids in the group treated with TB511 was significantly reduced in a TB511 concentration-dependent manner ( *** p<0.001)( Fig.29 ). In addition, the results of fluorescent staining of the spheroids to confirm the results of related markers on the 10th day after drug treatment showed that the number of THP-1 cells in the TB511-treated group was significantly reduced in a concentration-dependent manner compared to the group not treated with TB511, and the tumor growth factor ki-67 also showed a tendency to decrease (**p < 0.01, *** p<0.001)( Fig.30 ).

[0207] Example 10. Confirmation of ADC efficacy in three-dimensional cancer organoids

[0208] 10-1. Confirmation of the effect of ADC in 3D breast cancer organoids

[0209] In order to confirm the efficacy of ITGB2-binding ADC against breast cancer, MDA-MB-231 human breast cancer cells, CAF and THP-1 cells were mixed by the method of Example 8-1 to form three-dimensional spheroids, and CD18-DM1 or CD18-MMAE, which are ADCs of the present invention, were treated at concentrations of 10 μg and 20 μg, respectively, and the effects were analyzed by the same method as in Example 8-1.

[0210] The results showed that the size of breast cancer spheres in the group without ADC treatment gradually increased over time, but the size of spheres in the group with ADC treatment decreased from the 8th day ( Fig.31 and Fig.32 ). In addition, the number of GFP-positive THP-1 cells increased strongly in the group not treated with ADC, but decreased in a concentration-dependent manner in the group treated with CD18-DM1 or CD18-MMAE ( *** p<0.001)( Fig.31 and Fig.32 ).

[0211] 10-2. Confirmation of the effect of ADC in lung cancer 3D organoids

[0212] In order to confirm the efficacy of ADC against lung cancer, A549 human lung cancer cells, CAF and THP-1 cells were mixed by the method of Example 8-1 to form three-dimensional spheroids, and CD18-DM1 or CD18-MMAE, which are ADCs of the present invention, were treated at a concentration of 10 μg, and the effects were analyzed by the same method as in Example 8-1.

[0213] The results showed that the size of the spheroids in the group without ADC treatment gradually increased over time. On the contrary, the size of the spheroids in the group treated with CD18-DM1 or CD18-MMAE began to decrease from the 8th day ( Fig.33 ). In addition, the results of fluorescent staining of the spheroids to confirm the results of related markers on the 8th day after drug treatment showed that THP-1 cells increased strongly in the group not treated with ADC, while in contrast, they decreased significantly in the group treated with ADC ( *** p<0.001)( Fig.34 ).

[0214] Example 11. Confirmation of ADC efficacy in anticancer agent-resistant three-dimensional cancer organoids

[0215] 11-1. Confirmation of the effect of ADC in three-dimensional organoids of lung cancer resistant to anticancer drugs

[0216] In order to confirm the efficacy of ADC against carboplatin-resistant lung cancer, carboplatin-resistant A549 cells, CAF and THP-1 cells were mixed by the method of Example 8-1 to form three-dimensional spheres, and then CD18-DM1 or CD18-MMAE were treated at a concentration of 10 μg, respectively, and the effects were analyzed by the same method as in Example 8-1.

[0217] The results showed that the size of the spheroids in the group without ADC treatment gradually increased over time. On the contrary, the size of the spheroids in the group treated with CD18-DM1 or CD18-MMAE began to decrease from the 8th day ( Fig.35 ). In addition, the results of fluorescent staining of the spheres on the 8th day after drug treatment to confirm the results of related markers showed that the number of THP-1 cells in the groups treated with CD18-DM1 or CD18-MMAE was significantly reduced compared with the groups not treated with ADC, and the tumor growth factor ki-67 was also reduced ( *** p<0.001)( Fig.36 ).

[0218] 11-2. Confirmation of the effect of ADC in three-dimensional organoids of prostate cancer resistant to anticancer drugs

[0219] In order to confirm the efficacy of ADC against docetaxel-resistant prostate cancer, docetaxel-resistant PC3 prostate cancer cells, CAF and THP-1 cells were mixed to form three-dimensional spheres by the method of Example 8-1 above, and then CD18-DM1 or CD18-MMAE were treated at a concentration of 10 μg respectively and their effects were analyzed by the same method as in Example 8-1 above.

[0220] The results showed that the size of the spheroids in the group without ADC treatment gradually increased over time. In contrast, the size of the spheroids in the group treated with CD18-DM1 or CD18-MMAE decreased from day 8 ( Fig.37 ). In addition, the results of immunofluorescence staining of the spheroids to analyze related markers on the 8th day after drug treatment showed that the fluorescence in the group without ADC treatment increased strongly. On the contrary, the number of THP-1 cells in the group treated with CD18-DM1 or CD18-MMAE decreased significantly, and the tumor growth factor ki-67 also decreased ( *** p<0.001)( Fig.38 ).

Claims

1. A pharmaceutical composition for removing tumor-associated macrophages in a tumor microenvironment, characterized in that: The invention comprises a conjugate in which beet venom peptide, its variant or its analogue is combined with a pro-apoptotic peptide or an anticancer agent as an effective ingredient.

2. The pharmaceutical composition for removing tumor-associated macrophages in a tumor microenvironment according to claim 1, characterized in that: Tumor-associated macrophages are M2-type tumor-associated macrophages that express integrin β2.

3. The pharmaceutical composition for removing tumor-associated macrophages in a tumor microenvironment according to claim 1, characterized in that: Melittin, its variants or their analogs specifically bind to the extended active conformation of CD18.

4. The pharmaceutical composition for removing tumor-associated macrophages in a tumor microenvironment according to claim 1, characterized in that: Melittin, its variants or analogs thereof bind to amino acids 449 and 466 to 565 of ITGB2.

5. The pharmaceutical composition for removing tumor-associated macrophages in a tumor microenvironment according to claim 1, characterized in that: Melittin comprises the amino acid sequence of SEQ ID NO:

1.

6. The pharmaceutical composition for removing tumor-associated macrophages in a tumor microenvironment according to claim 1, characterized in that: The variant of melittin comprises the amino acid sequence of sequence 2.

7. The pharmaceutical composition for removing tumor-associated macrophages in a tumor microenvironment according to claim 1, characterized in that: The connection is through a linker.

8. The pharmaceutical composition for removing tumor-associated macrophages in a tumor microenvironment according to claim 7, characterized in that: The linker comprises the amino acid sequence of SEQ ID NO:

3.

9. The pharmaceutical composition for removing tumor-associated macrophages in a tumor microenvironment according to claim 1, characterized in that: A peptide comprising an amino acid sequence comprising sequence 5 or sequence 6.

10. The pharmaceutical composition for removing tumor-associated macrophages in a tumor microenvironment according to claim 1, characterized in that: The pro-apoptotic peptide is selected from the group consisting of KLA, α-defensin-1, BMAP-28, Brevenin-2R, Buforin IIb, cecropin A-magnacin 2, cecropin A, cecropin B, chrysophsin-1, D-K6L9, Gomesin, lactoferrin peptide B, LLL27, LTX-315, magainin 2, magainin II-beast antimicrobial peptide conjugate, parrot toxin and a combination thereof.

11. The pharmaceutical composition for removing tumor-associated macrophages in a tumor microenvironment according to claim 1, characterized in that: The anticancer agent is selected from 7-ethyl-10-hydroxycamptothecin, daunorubicin, doxorubicin, epirubicin, idarubicin, pixantrone, sabarubicin, valrubicin, paclitaxel, docetaxel, mechlorethamine, chlorambucil, phenylalanine, mechlorethamine, cyclophosphamide, ifosfamide, carmustine, lomustine, streptozotocin, busulfan, thiotepa, cisplatin, carboplatin, actinomycin D, plicamycin, mitomycin C, vincristine, vinblastine, teniposide, topotecan, irinotecan, uramustine, melphalan, bendamustine, dacarbazine, temozolomide, hexamethasone, The invention is selected from the group consisting of duocarmycin, nedaplatin, oxaliplatin, satraplatin, triplatinium tetranitrate, 5-fluorouracil, 6-mercaptopurine, capecitabine, cladribine, clofarabine, cilastatin, floxuridine, fludarabine, gemcitabine, hydroxyurea, methotrexate, pemetrexed, pentostatin, mercaptoguanine, etoposide, mitoxantrone, ixabepilone, vindesine sulfate, isovinablastine, estramustine, maytansine, maytansine DM1, maytansine DM4, dolastatin, auristatin E, auristatin F, monomethyl auristatin E, monomethyl auristatin F and their derivatives.

12. A pharmaceutical composition for preventing or treating cancer, characterized in that: The invention comprises a conjugate in which beet venom peptide, its variant or its analogue is combined with a pro-apoptotic peptide or an anticancer agent as an effective ingredient.

13. The pharmaceutical composition for preventing or treating cancer according to claim 12, characterized in that: The cancer is one or more selected from the group consisting of brain tumor, melanoma, myeloma, non-small cell lung cancer, oral cancer, liver cancer, stomach cancer, colon cancer, breast cancer, triple-negative breast cancer, lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cervical cancer, ovarian cancer, colorectal cancer, small intestine cancer, rectal cancer, fallopian tube cancer, perianal cancer, endometrial cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, lymph node cancer, bladder cancer, gallbladder cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, kidney or ureter cancer, renal cell carcinoma, renal pelvis cancer, central nervous system tumor, primary central nervous system lymphoma, spinal cord tumor, brain stem glioma and pituitary adenoma.

14. The pharmaceutical composition for preventing or treating cancer according to claim 12, characterized in that: The cancer is an anticancer agent-resistant cancer.

15. The pharmaceutical composition for preventing or treating cancer according to claim 12, characterized in that: The drug is administered to patients whose expression of ITGB2 in M2 macrophages is upregulated compared with that in M0 macrophages and M1 macrophages.

16. A method for treating cancer, characterized in that: The method comprises the step of administering a pharmaceutically effective amount of a conjugate of melittin, its variants or their analogs combined with a pro-apoptotic peptide or an anti-cancer agent to an individual suffering from cancer.

17. Use of a conjugate of melittin, its variants or their analogs combined with a pro-apoptotic peptide or an anticancer agent in the preparation of a pharmaceutical composition for preventing and treating cancer.